ArticleBreast cancer research and treatment2026
Automated calculation of background parenchymal enhancement as a biomarker of treatment responses and recurrence-free survival in breast cancer.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine whether automated quantification of background parenchymal enhancement (BPE) from dynamic contrast-enhanced MRI (DCE-MRI) can serve as an imaging biomarker for clinical outcomes including overall survival (OS), recurrence-free survival (RFS), and pathological complete response (pCR) in breast cancer.
methodsThe multi-institutional data consisted of 922 biopsy-confirmed invasive breast cancer patients from the Duke-Breast-Cancer-MRI dataset and 152 patients with whole-breast pre- (T
resultsPeak-contrast BPE showed strong correlation with radiologist-defined BPE, achieving the best performance at a 55% signal enhancement threshold (AUC 0.70-0.86). The calculated BPE decreased after neoadjuvant chemotherapy. A reduction in calculated BPE grade after neoadjuvant chemotherapy was predictive of pCR for the high baseline BPE group (adjusted odds ratio = 5.88 [1.03, 33.33]) and for the low baseline BPE group (adjusted odds ratio = 6.54 [1.26, 33.94]). Baseline BPE was independently associated with improved OS (adjusted hazard ratio 0.58 [0.34, 0.99]) but not associated with RFS.
conclusionAutomated quantification of BPE from DCE-MRI provides an objective and reproducible imaging biomarker associated with treatment response and overall survival in breast cancer. These results support its potential utility for individualized risk stratification and therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.